The content on this page is designed for Australia. Check courses designed for Canada (EN)

This course has expired. View available courses.

Endocrinology

GLP-1RAs: Rethinking treatment intensification in people with T2D – ACRRM

It is well established that optimising glycaemic management decreases the risk of microvascular and macrovascular complications. A reduction of 1% glycated haemoglobin (HbA1c) has been associated with reductions in microvascular complications by 37%, myocardial infarction by 14% and death related to diabetes by 21%. Delayed treatment intensification to injectable therapy may be due to a myriad of reasons that may include concerns regarding problematic hypoglycaemia, complex or burdensome regimens, interference with daily living, social stigma and weight gain. Fear of hypoglycaemia was identified as a key barrier to treatment intensification. 75.5% of healthcare professionals reported they would treat more aggressively if it weren’t for the risk of hypoglycaemia with insulin.

DURATION

1 hr

PROFESSION

Physician

# OF CREDITS

1

ACCREDITATION

ACRRM

EXPIRY DATE

2020-11-30

It is well established that optimising glycaemic management decreases the risk of microvascular and macrovascular complications. A reduction of 1% glycated haemoglobin (HbA1c) has been associated with reductions in microvascular complications by 37%, myocardial infarction by 14% and death related to diabetes by 21%. Delayed treatment intensification to injectable therapy may be due to a myriad of reasons that may include concerns regarding problematic hypoglycaemia, complex or burdensome regimens, interference with daily living, social stigma and weight gain. Fear of hypoglycaemia was identified as a key barrier to treatment intensification. 75.5% of healthcare professionals reported they would treat more aggressively if it weren’t for the risk of hypoglycaemia with insulin.

Faculty

Mark Kennedy
MBBS, BMedSc(Hons), GradDipFamMed
Clinical Associate Professor of General Practice
The University of Melbourne, Melbourne, VIC
Director, Corio Medical Clinical and Coria Diabetic Clinic, Geelong, VIC

Sultan Linjawi
BSc, MBBS, MRCP, FRACP
Director, My Health Explained, Brisbane, QLD
Director and Consultant Physician
(Endocrinology and Diabetes)
Coffs Endocrine and Diabetes Services, Coffs Harbor, NSW

Accreditation

This online CME event is an Accredited Distance/Remote based education module as defined by the Professional Development Program of the Australian College of Rural and Remote Medicine. ACRRM member participation and information will be noted and sent directly to the ACRRM for accreditation processing. Please allow 30 days for ACRRM to send you your points. This activity is approved for 1 Core Point(s).
Cost of course:  
Free
# of credits: 1
Duration: 1 hr

FAQs & HELP

MDBriefCase Group specializes in accredited, online continuing professional development (CPD) programs, custom tailored for specific international markets and available on a convenient online platform.

All content is developed by leading specialists and peer-reviewed by experts at respected institutions, which keeps more than 280,000 global healthcare professionals at the forefront of the latest evidence and protocols worldwide.

The vast majority of our programs are accredited by one or more respected institutions. We do provide unaccredited content to ensure that healthcare professionals have access to relevant practical resources in addition to accredited learning.

Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.

MDBriefCase Group works with various institutions to provide peer-reviewed, up-to-date accredited content. Our programs and resources are provided via collaboration between medical writers, faculty members, associations, universities and other relevant organizations. The content you were recommended is likely valued by your society or association and is conveniently provided to you free of charge on an MDBriefCase Group platform.

Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.

No, registration with MDBriefCase is free!

To access your profile, visit My Profile. If you would like to update the information here don’t forget to hit the ‘save’ button when you are finished. Your profile is where you can control what email communications you receive.

If you have forgotten your password, you can reset your password. To access this page from the Login page, click Forgot password. Enter the email address you registered with and you will receive an email with a link to reset your password.

Please note: if you submitted multiple password resets, only the link on the most recent email is valid.

You can unsubscribe from MDBriefCase Group emails by clicking the unsubscribe button located at the bottom of each of our emails.

GLP-1RAs: Rethinking treatment intensification in people with T2D – ACRRM

1 hr

Duration

Physician

Profession

1

# of credits

Learning Objectives

ACF Learning Objectives

ACRRM

ACCREDITATION

Endocrinology

Learning Category

General

Topic

0

Price

2020-11-30

Expiry Date

AUS

Region/Language

Course Description

It is well established that optimising glycaemic management decreases the risk of microvascular and macrovascular complications. A reduction of 1% glycated haemoglobin (HbA1c) has been associated with reductions in microvascular complications by 37%, myocardial infarction by 14% and death related to diabetes by 21%. Delayed treatment intensification to injectable therapy may be due to a myriad of reasons that may include concerns regarding problematic hypoglycaemia, complex or burdensome regimens, interference with daily living, social stigma and weight gain. Fear of hypoglycaemia was identified as a key barrier to treatment intensification. 75.5% of healthcare professionals reported they would treat more aggressively if it weren’t for the risk of hypoglycaemia with insulin.

Faculty

Mark Kennedy
MBBS, BMedSc(Hons), GradDipFamMed
Clinical Associate Professor of General Practice
The University of Melbourne, Melbourne, VIC
Director, Corio Medical Clinical and Coria Diabetic Clinic, Geelong, VIC

Sultan Linjawi
BSc, MBBS, MRCP, FRACP
Director, My Health Explained, Brisbane, QLD
Director and Consultant Physician
(Endocrinology and Diabetes)
Coffs Endocrine and Diabetes Services, Coffs Harbor, NSW

Accreditation

This online CME event is an Accredited Distance/Remote based education module as defined by the Professional Development Program of the Australian College of Rural and Remote Medicine. ACRRM member participation and information will be noted and sent directly to the ACRRM for accreditation processing. Please allow 30 days for ACRRM to send you your points.
This activity is approved for 1 Core Point(s).